Introduction 39
Tuberculosis (TB) is the leading cause of mortality due to a bacterial 40 pathogen, Mycobacterium tuberculosis (Mtb). There were 8.7 million new cases 41 of TB in 2011, which claimed 1.4 million lives (1). The complexity and length of 42 the current TB treatment often leads to patient non-compliance and Mtb has 43 adapted to this sub-optimal pharmacological stress by evolving multi-drug 44 resistant strains (MDR-TB) and extensively drug resistant strains (XDR-TB) (2). 45 with strains that are resistant to all of the available first-line drugs and most of the 48 second-line drugs were recently reported (3). Another major concern is that the 49 most recent first-line TB drug discovery occurred almost 50 years ago with 50 rifampin in 1963, and since then the panel of drugs has changed only modestly 51 while treatments have gained in complexity because of the emergence of 52 resistant strains (4). Therefore, the need for new classes of drugs that use 53 diverse mechanisms to prevent bacterial growth continues to increase in 54 urgency. 55
Lsr2 is a nucleoid-associated protein encoded by Mtb and other 56 actinobacteria that binds AT-rich DNA. Lsr2 appears to be functionally analogous 57 to H-NS nucleoid-associated proteins found in E. coli and related bacteria as well 58 as eukaryotic histone proteins (5, 6) . This functionality imparts to the genomic 59 DNA resistance to oxidative damage and is essential for Mtb viability (7). More 60 importantly, Lsr2 binds AT-rich regions in the otherwise GC-rich mycobacterial 61 genome and thereby represses transcription of a large number of genes and is 62 shown to play a major role in suppressing expression of exogenous DNA from 63 transposons and mycobacterial phages (8, 9) . Cross-linking studies showed that 64
Lsr2 binds to a portion of more than 20% of the genes identified in the Mtb 65 genome (9). In addition to identifying the lsr2 gene as a target for Lsr2 binding, 66
the same study showed that many of the genes bound by Lsr2 are important for 67 the mycobacterial response to environmentally induced stress such as the 68 on July 8, 2017 by guest http://aac.asm.org/
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Running title: Zafirlukast inhibits Mtb Lsr2 function. 5 presence of antibiotics, oxidative stress and production of virulence factors, as 69 well as genes that affect cell proliferation and persistence (10-14). Therefore, 70
targeting Lsr2 with small molecule inhibitors of DNA binding may severely 71 dysregulate the transcription of a wide array of important Mtb genes, ultimately 72 leading to unhealthy mycobacteria that are unable to mount their typical defenses 73 against the human immune system during infection or the current treatment 74 regimen. To date, no research groups have described compounds that inhibit 75 DNA binding by Lsr2. 76
Here we report the development of a high-throughput binding assay that 77 monitors complex formation between Lsr2 and AT-rich DNA in vitro. This assay 78 afforded the identification of Zafirlukast as an inhibitor of the complexation 79 between Lsr2 and DNA. Zafirlukast is a cysteinyl leukotriene receptor (CysLT1) 80 antagonist that readily migrates to lung tissue and is currently used as a 81
prophylactic treatment for asthma. Experiments Tris pH 7.5, 1 M NaCl, 10 % glycerol, 5 mM β-mercaptoethanol, 250 mM 96 imidazole) on a 5 mL HisTrap FF column (GE Healthcare). Following tag 97 cleavage by application of prescission protease during dialysis to remove excess 98 imidazole, the thioredoxin-polyhistidine tag and protease were removed using 99 immobilized metal affinity chromatography. Fractions containing Lsr2 were 100 pooled and further purified using cation exchange chromatography (Wash buffer: 101 20 mM Mes pH 6.0, 10 % glycerol, 0.5 mM TCEP, 1 mM EDTA, 150 mM NaCl 102 and Elution buffer: 20 mM Mes pH 6.0, 10 % glycerol, 0.5 mM TCEP, 1 mM 103 EDTA, 1 M NaCl) on a 5 mL HiTrap SP FF column (GE Healthcare). without SuperScript III or RNA were also performed. PCR products were run on a 164 1% agarose gel and stained with SYBR Safe DNA gel stain (Invitrogen), followed 165 by band intensity quantification with the Quantity One software (Bio-Rad). 166
Primers used for these experiments are shown in Supplementary Table 1 . Screening of the NIH Clinical Collection identified seven compounds as potential 223 leads based on a criterion of an FP signal decrease greater than three times the 224 standard deviation from the mean polarization measurement. Of these, six are 225 known DNA intercalators or groove binders so they were not studied further, 226 since the purpose of this study is to identify a compound that specifically inhibits 227
Lsr2 function. The single remaining lead from this screening study, Zafirlukast, is 228 a leukotriene receptor antagonist commonly prescribed as a prophylactic 229 treatment for asthma ( Fig. 1B) . To determine the inhibitory constant (K i ) for 230
Zafirlukast, a dose-dependence study using the same basic FP assay as 231 described above was used (Fig. 1C) . However, the concentrations of both the 232 13 (15, 16) . Samples containing fixed concentrations of Ritonavir, as an internal 243 standard, and Zafirlukast were exposed to varying Lsr2 concentrations. 244
Subsequent MALDI-TOF experiments monitored the intensity of the Zafirlukast 245 and Ritonavir ion peaks ( Fig. 2A) . Comparing the relative ion abundance of the 246 two drugs from each of the mixtures shows that the ratio of free Zafirlukast to 247
Ritonavir ions decreases as the concentration of Lsr2 increases (Fig. 2B) . The 248 decrease in the relative ion intensity of Zafirlukast can be directly attributed to its 249 binding with Lsr2 and its removal from the pool of unbound Zafirlukast. 250 251
Zafirlukast inhibits the growth of mycobacteria. To assess the ability of 252
Zafirlukast to enter the mycobacterial cell, inhibit Lsr2 function and affect cell 253 growth, a Kirby-Bauer disk diffusion assay was performed using either 254
Mycobacterium smegmatis or the attenuated Mtb strain mc 2 6230 ( Fig. 3A & B) . 255
Various amounts of Zafirlukast (49-392 μg) were used since it was unknown to 256 what extend the drug would inhibit growth. Following incubation, the plate 257 exhibited clear zones of inhibition whose size is concomitant with increasing 258 amounts of drug. 259
It is typical for anti-mycobacterial compounds to have better efficacy 260 against M. smegmatis than Mtb, so it was expected that Mtb would not respond 261 as strongly to Zafirlukast. To account for this, a Zafirlukast dose of 500 μg was 262 used for the Mtb mc 2 6230 Kirby-Bauer growth assay. As expected, the zone of 263 inhibition when testing M. smegmatis growth in the presence of 392 μg drug was 264 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from larger than that observed when using 500 μg for Mtb. When exposing a 265 laboratory strain of E. coli to the same amount of compound exhibits no growth 266 inhibition (Fig. 3C) . 267
These data clearly show that E. coli, which does not encode an Lsr2 conditions. Following addition of Zafirlukast, a time course over a seven-day 302 period shows a significant decrease in colony forming units (Fig. 4) 
Zafirlukast increases gene expression in genes bound by Lsr2. To gain 311
information concerning the mechanism of growth inhibition by Zafirlukast, semi-312 quantitative reverse transcriptase PCR was used to examine the effects of 313 administering the drug on transcription of five Mtb genes previously shown to be 314 bound by Lsr2 (9) (Fig. 5) . Two of the inspected genes, otsA and fbpC, were 315 chosen because they play important roles in synthesizing trehalose and the 316 mycobacterial outer membrane, respectively (14, 17, 18) . The third gene, sodA, 317 encodes the superoxide dismutase virulence factor (19). As it is known that the 318 Lsr2 protein binds its own gene, lsr2, the mRNA levels of that gene were also 319 quantified (9). A constitutively expressed housekeeping gene, sigA, was 320 examined as a standard. Two different cultures were exposed to Zafirlukast and 321 RNA was extracted from each sample. Two different concentrations of RNA, 5 322 and 10 ng, were used for amplification of the selected genes and the intensity of 323 the resulting bands from two replicates from each of the two cultures were 324 quantified. These experiments consistently show that addition of Zafirlukast 325 promotes the increase of gene expression in the four mycobacterial genes known 326 to be bound by Lsr2. 327
The largest increase observed was in the mRNA levels of lsr2, which 328 inhibitor of the complexation between Lsr2 and DNA. This inhibition occurs 342 through direct interactions between the drug and the protein, which is supported 343 by the Intensity Fading MALDI-TOF mass spectrometry data. We have shown 344 using Kirby-Bauer disk diffusion assays that Zafirlukast was able to enter the 345 mycobacterial cell and effectively inhibit the growth of M. smegmatis and Mtb in a 346 concentration-dependent manner. 347
Since it is known that mycobacteria can form drug-insensitive clusters or 348 when Zafirlukast is applied. This suggests that the response triggered by the 361 administration of Zafirlukast results from a mechanism different from the 362 antibiotic-induced stress caused by known anti-tubercular drugs. Therefore, it is 363 reasonable to suggest that Zafirlukast is acting through a novel molecular 364 mechanism (22-25). 365
The first of two possible mechanisms by which Zafirlukast inhibition of Lsr2 366 could lead to growth inhibition of mycobacteria is by strongly stimulating 367 transcription of the lsr2 gene. This overexpression would saturate the 368 mycobacterial genomic DNA with Lsr2 protein, which would strongly inhibit 369 expression of genes important for growth. However, that hypothesis is not 370 consistent with the presented RT-PCR data that shows a general increase in 371 transcription of the studied genes. A recent example of mycobacterial toxicity due to metabolite accumulation 385 in mycobacteria was shown by Kalscheuer et al. (28) . This paper showed that in 386 a GlgE knock-out the accumulation of maltose 1-phosphate promotes the 387 increased expression of enzymes necessary for production of the toxic 388 metabolite, thereby producing a positive feedback loop that promotes rapid killing 389 of Mtb. However, the mechanism of killing is not yet known. 390
In E. coli, it is known that NADH dehydrogenase I expression is up-391 regulated in response to bactericidal drugs. This promotes hydroxyl-radical 392 production that promotes DNA damage and a subsequent SOS response (29) . It 393 has been shown that M. smegmatis NADH dehydrogenase mutants with 394 Lsr2-Zafirlukast complex. The strong induction of lsr2 transcription exhibited in 408 the RT-PCR data suggests that the expression of lsr2 is highly regulated by Lsr2 409 activity and therefore highly sensitive to inhibitors of Lsr2-DNA binding activity. In 410 such a case, inhibition of only half of the Lsr2 proteins in a mycobacterial cell 411 may still have extreme effects on transcription of lsr2 or other genes whose over-412 expression may lead to cell death. Ultimately, a global analysis of mycobacterial 413 transcription levels in response to Zafirlukast application is required to more 414 clearly assess the mechanism of growth inhibition. 415
This study aimed to identify inhibitors of Lsr2 DNA-binding activity for the 416 development of novel antitubercular compounds. Even though the exact 417 mechanism of action by which this inhibition occurs is still under study, the 418 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from 
